Gentel Biosciences, a leader in proteomics tools, and Van Andel Research Institute (VARI), a biomedical research institute, jointly announce today the granting of U.S. Patent 7,838,634 for a new method to profile changes in the glycosylation of proteins captured on the surface of an antibody array slide. Gentel first obtained an exclusive right to commercialize the technology in 2006.
According to Brian H. Haab, Ph.D., head of VARI's Laboratory of CancerImmunodiagnostics and inventor of the technology, "A number of new biomarkers using glycosylated variants of proteins have recently received or are proceeding toward FDA clearance. The ability to efficiently screen glycosylated variants of many proteins for use as biomarkers offers an unprecedented opportunity for discoveries of new glycan-based biomarkers."
Glycosylation is the addition of linear or branched sugar molecules to proteins. Many studies have shown that glycosylated variants of proteins can make better markers for early detection and for prognosis in cancers like hepatocellular carcinoma when compared to measuring the protein alone.
"There is a lack of tools to screen proteins for changes in glycosylation that might be associated with disease. Dr. Haab's approach is a better method to identify new diagnostic biomarkers based on glycosylated variants of proteins," added Bryce P. Nelson, Ph.D., Vice President of Technology and Business Development at Gentel Biosciences.
A patent for the technology is also pending in the European Union.
The new glycan detection technology will soon be combined with the more than fifty SilverQuant- Antibody Array kits available from Gentel. These antibody array kits target nearly 500 proteins and provide a complete proteomics workflow from screening to quantification. SilverQuant kits are configured for use with the Gentel Proteomics Multi-System- and Gentel's AthenaQuant- analysis software for an easy-to-use and cost-effective alternative with better sensitivity than fluorescence-based detection. SilverQuant chromogenic technology allows for the detection of any biotinylated molecule, generating array spots that are visible to the naked eye that can be detected with the Gentel Proteomics Multi-System. Simple protocols empower both experts and novices to obtain meaningful protein multiplexing data in a single day.
Source: Van Andel Research Institute
Gentel生物科学，在蛋白质组学工具的领导者，温安洛研究所（可变交叉），生物医学研究所，今天联合宣布批出的新方法向美国专利7838634剖面中的蛋白质对糖基化改变的表面捕获抗体芯片的幻灯片。 Gentel首次获得了独家权利，在2006年商业化的技术。
根据Brian阁下哈布，博士，乐妓的癌症免疫诊断实验室和技术的发明者，“一个使用最近收到的蛋白质糖基化的变种或新的生物标志物进行一些对FDA的批准。能够有效地屏幕糖化许多蛋白质变种使用作为生物标志物提供了一个新的糖链为基础的生物标志物发现前所未有的机遇。“
糖基化是线性或支糖分子的蛋白质增加。许多研究表明，蛋白质糖化变种可以更好地为早期诊断标志物和肿瘤如肝癌预后的测量相比，单独的蛋白质。